The immersive new exhibit will now open next year. Image courtesy of Houston Zoo

Houstonians eager to meet sea lions, giant tortoises, sharks, and Humboldt penguins at the Houston Zoo will have to wait a bit longer, the zoo announced.

Galápagos Islands, the highly immersive Houston Zoo experience showcasing one of the most pristine, ecologically rich areas in the world, will not open until early 2023.

The Galápagos exhibit is part of the zoo’s 100th anniversary celebration and was slated to open fall of this year. Zoo officials cite supply chain issues for key construction materials — such as acrylic viewing panels for the state-of-the-art sea lion habitat — as the reason for the delay.

This planned exhibit is the first of its kind to showcase the wildlife of the legendary island chain that Charles Darwin studied and made famous.Guests can dive into an environment evoking the archipelago’s unique landscapes and oceanic habitats — all meant to inspire intrigue and preservation.

One major draw should be the Galápagos penguins, which are threatened by overfishing, ocean pollution, and climate change and are highly protected by the Ecuadorian government. It is the most threatened penguin species in the world, the zoo notes, with an estimated population of less than 2,000 individuals.

The Galápagos is often heralded as the planet’s ultimate area spotlighting unique species, the delicate balance of ecosystems, and the pressing need for conservation action, the zoo notes.

“We’re disappointed that the project has been delayed, but we know we’re not alone in experiencing supply chain problems,” said Houston Zoo president and CEO Lee Ehmke in a statement. “Our commitment to conservation in the Galápagos Islands, our animal residents, and our guests here in Houston remain unwavering. A short delay in our exhibit opening will not deter us from our mission of connecting communities to animals, inspiring action to save wildlife.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.